Apogee Pharmaceuticals Inc. has prepared fatty acid amide hydrolase (FAAH) inhibitors reported to be useful for the treatment of cancer, pain, inflammation, anxiety and mood disorders, cardiovascular disorders, autoimmune diseases and neurological disorders, among others.
The University of Minnesota has patented flavones having senolytic activity that are described as useful for the treatment of aging and Hutchinson-Gilford progeria syndrome.
Heterocyclic insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves’ ophthalmopathy) have been disclosed in a Horizon Therapeutics Ltd. patent.
Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a payload. They are described as potentially useful for the treatment of non-small-cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Brii Biosciences Inc. has identified substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives that are prodrugs of thyroid hormone receptor β (TH-β) agonists and reported to be useful for the treatment of multiple sclerosis.
A recent patent application from Laleh Rad, associate professor of Biomedical Engineering and Radiology at Northwestern University, describes the use of machine learning for real-time risk assessment of magnetic resonance imaging in patients with conductive implants for whom tissue heating from radiofrequency excitation fields remains a major concern.
TB Alliance has disclosed new ATP-dependent Clp protease ClpP1P2 complex (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis.
Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.
RSS
